鉴别胰腺良恶性肿块:Ga-68 PSMA PET/CT 作为新的诊断途径
该前瞻性研究纳入40例常规影像发现胰腺病变的患者,均行全身F-18 FDG PET/CT和腹部Ga-68 PSMA PET/CT,以病理/细胞学为参考标准。PSMA PET/CT诊断恶性病变的敏感度94.7%、特异度90.5%、准确率92.5%,均高于FDG PET/CT(89.5%、57.1%、72.5%);PSMA SUVmax 4.8可预测恶性潜能(特异度90.5%、敏感度84.2%)。
要点
- Ga-68 PSMA PET/CT诊断胰腺恶性病变的准确率92.5%,高于FDG PET/CT的72.5%。
- PSMA SUVmax阈值4.8预测恶性潜能:特异度90.5%、敏感度84.2%。
- FDG PET/CT在炎症性病变中可能出现假阳性,本组假阳性9例。
关键影像表现/征象
- PET图像上局灶性示踪剂摄取(FDG或PSMA)被视为阳性。
- FDG PET/CT结果:真阳性17例、假阳性9例、真阴性12例、假阴性2例。
- PSMA PET/CT结果:真阳性18例、假阳性2例、真阴性19例、假阴性1例。
诊断标准与关键数值
- FDG PET/CT诊断恶性病变的敏感度89.5%、特异度57.1%、PPV 65.4%、NPV 85.7%、准确率72.5%。
- PSMA PET/CT诊断恶性病变的敏感度94.7%、特异度90.5%、PPV 90%、NPV 95%、准确率92.5%。
- PSMA PET/CT的SUVmax值4.8可预测病变的恶性潜能,特异度90.5%、敏感度84.2%。
临床应用与阅片要点
- Ga-68 PSMA PET/CT在鉴别胰腺良恶性病变时表现出比FDG PET/CT更高的PPV(90.5% vs. 65.4%)和准确率(92.5% vs. 72.5%)。
- FDG PET/CT可能因炎症性病变出现假阳性,本组假阳性9例,可能偶尔妨碍其鉴别良恶性病变的能力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: Differentiation of malignant and benign pancreatic lesions on anatomical imaging is difficult in some cases with overlapping features. Prostate-specific membrane antigen (PSMA) is overexpressed during angioneogenesis in many tumors. We aimed to evaluate the PSMA expression in pancreatic lesions to differentiate these lesions and explore the performance of Ga-68 PSMA-PET/CT vis-a-vis F-18 FDG-PET/CT.
METHODS: Patients with pancreatic lesions on conventional imaging were prospectively recruited. All the patients underwent a whole-body F-18 FDG-PET/CT and a regional abdominal Ga-68 PSMA-PET/CT. Focal tracer uptake (FDG or PSMA) on PET images was considered positive. Histopathology and/or cytopathology were considered the reference standard.
RESULTS: A total of forty patients (27 males, mean age 55.3 ± 9.8, range 37-71 years) were enrolled. Of these, 19 were diagnosed as malignant on histopathology/cytology. Patients with benign lesions showed no worsening of symptoms for at least 6 months on follow-up. FDG-PET/CT revealed 17 true-positive (TP), 9 false-positive (FP), 12 true-negative (TN), and 2 false-negative (FN) findings, whereas PSMA-PET/CT had 18 TP, 2 FP, 19 TN, and 1 FN finding. The sensitivity, specificity, PPV, NPV, and accuracy for FDG-PET/CT were 89.5%, 57.1%, 65.4%, 85.7%, and 72.5%, respectively, while for PSMA-PET/CT were 94.7%, 90.5%, 90%, 95%, and 92.5%, respectively. ROC curve analysis showed that the SUVmax value of 4.8 on PSMA-PET/CT could predict the malignant potential of a lesion with a specificity of 90.5% and a sensitivity of 84.2%.
CONCLUSIONS: Ga-68 PSMA-PET/CT imaging helped in establishing a non-invasive pre-operative diagnosis of primary pancreatic malignancy with a higher degree of specificity and accuracy compared with FDG-PET/CT.
KEY POINTS: • Conventional imaging such as CT and MRI are unable to reliably differentiate localized malignant pancreatic lesion from benign lesions mimicking malignancy such as mass-forming pancreatitis. • FDG PET/CT helps in detecting malignant foci in view of their increased glucose metabolism. However, it may be falsely positive in inflammatory lesions which may occasionally hinder its ability to differentiate between benign and malignant lesions. • Apart from prostatic malignancy, PSMA is overexpressed in neovasculature of many non-prostatic malignancies. The present study highlights that Ga68 PSMA PET/CT performed better in diagnosing malignancy non-invasively than FDG-PET/CT with a higher PPV (90.5% vs. 65.4%) and accuracy (92.5% vs. 72.5%).
引用
- Krishnaraju VS, Kumar R, Mittal BR, et al. Differentiating benign and malignant pancreatic masses: Ga-68 PSMA PET/CT as a new diagnostic avenue. Eur Radiol. 2020. PMID: 33001304. doi:10.1007/s00330-020-07318-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。